Nothing Special   »   [go: up one dir, main page]

PE20081596A1 - Derivados fluorinados de deferiprona - Google Patents

Derivados fluorinados de deferiprona

Info

Publication number
PE20081596A1
PE20081596A1 PE2008000549A PE2008000549A PE20081596A1 PE 20081596 A1 PE20081596 A1 PE 20081596A1 PE 2008000549 A PE2008000549 A PE 2008000549A PE 2008000549 A PE2008000549 A PE 2008000549A PE 20081596 A1 PE20081596 A1 PE 20081596A1
Authority
PE
Peru
Prior art keywords
iron
ona
alkyl
deferiprone
compounds
Prior art date
Application number
PE2008000549A
Other languages
English (en)
Inventor
Tim Fat Tam
Regis Leung-Toung
Yingsheng Wang
Yanqing Zhao
Original Assignee
Apotex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Technologies Inc filed Critical Apotex Technologies Inc
Publication of PE20081596A1 publication Critical patent/PE20081596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS FLUORINADOS DE DEFERIPRONA DE FORMULA (I) DONDE Y ES NR1, EN DONDE R1 ES H, ALQUILO(C1-C6), CICLOPROPILMETILO, ALILO O CICLOPROPILO; R2 ES H, ALQUILO(C1-C4) O R5CHOH, EN DONDE R5 ES H, ALQUILO(C1-C3) O TRIFLUOROMETILO; R3 ES METILO, H O CF3CHOH; R4 ES CHF2. SON COMPUESTOS PREFERIDOS: 2-DIFLUOROMETIL-5-HIDROXI-PIRAN-4-ONA, 2-DIFLUOROMETIL-5-HIDROXI-1-METIL-1H-PIRIDIN-4-ONA, 1-CICLOPROPIL-2-DIFLUOROMETIL-5-HIDROXI-1H-PIRIDIN- 4-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON QUELANTES DE HIERRO UTILES EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS CAUSADAS POR LA PRESENCIA DE HIERRO LIBRE O ACUMULACION DE HIERRO EN TEJIDOS NEURONALES Y EN ENFERMEDADES DONDE EL EXCESO DE HIERRO DEBE SER REMOVIDO O REDISTRIBUIDO
PE2008000549A 2007-03-28 2008-03-27 Derivados fluorinados de deferiprona PE20081596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90729007P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
PE20081596A1 true PE20081596A1 (es) 2009-02-05

Family

ID=39743019

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000549A PE20081596A1 (es) 2007-03-28 2008-03-27 Derivados fluorinados de deferiprona

Country Status (15)

Country Link
US (2) US8026261B2 (es)
EP (1) EP2134688B1 (es)
CN (2) CN102964296B (es)
AR (1) AR065880A1 (es)
AU (1) AU2008232262B2 (es)
CA (2) CA2681545C (es)
CL (1) CL2008000887A1 (es)
IL (1) IL201189A (es)
MX (1) MX2009010407A (es)
NZ (2) NZ600874A (es)
PE (1) PE20081596A1 (es)
TW (1) TWI404533B (es)
UY (1) UY30986A1 (es)
WO (1) WO2008116301A1 (es)
ZA (1) ZA200906712B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404533B (zh) 2007-03-28 2013-08-11 Apotex Technologies Inc 去鐵酮（ｄｅｆｅｒｉｐｒｏｎｅ）之氟化衍生物
GB0803019D0 (en) * 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
BRPI0822206B8 (pt) * 2008-04-25 2021-05-25 Apotex Tech Inc formulação líquida para deferiprona com um sabor agradável.
CN102712591B (zh) * 2009-07-03 2014-06-25 阿普泰克斯科技公司 3-羟基吡啶-4-酮的氟化衍生物
DK2646436T3 (en) 2010-11-29 2015-06-29 Pfizer monobactams
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013073577A1 (ja) * 2011-11-15 2013-05-23 アステラス製薬株式会社 ジヒドロキシ芳香族へテロ環化合物
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
EP3016935B1 (en) * 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
US10802459B2 (en) 2015-04-27 2020-10-13 Ademco Inc. Geo-fencing with advanced intelligent recovery
US10516965B2 (en) 2015-11-11 2019-12-24 Ademco Inc. HVAC control using geofencing
US10605472B2 (en) 2016-02-19 2020-03-31 Ademco Inc. Multiple adaptive geo-fences for a building
WO2017152237A1 (en) * 2016-03-10 2017-09-14 The University Of Sydney Novel analogues of desferrioxamine b (dfob)
CN111170936B (zh) * 2020-01-19 2021-01-01 杭州泽德医药科技有限公司 3,4-二羟基-n-(1’-苄基-2’-羟乙基)-2-甲基吡啶氯化物及制备和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) * 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
BE639493A (es) 1962-12-20
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308054D0 (en) 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
USRE34313E (en) 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
GB8329043D0 (en) 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
DE3826846A1 (de) 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
CA2121435C (en) 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
AU695469B2 (en) 1994-01-31 1998-08-13 Pfizer Inc. Method of synthesizing gamma pyrones
WO1995027485A1 (en) 1994-04-08 1995-10-19 The Procter & Gamble Company Methods of using iron chelating compounds to reduce free radical damage in mammals
CA2172807C (en) 1994-08-01 1999-10-12 Keith S. Lienhop Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) * 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) * 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
WO2000012135A1 (fr) 1998-08-28 2000-03-09 Eisai Co., Ltd Compositions medicales presentant une amertume, etc., reduite
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
CA2440412A1 (en) 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
AU2003222513A1 (en) 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
EP1482789A4 (en) 2002-03-12 2010-12-29 Toyama Chemical Company Ltd TASTY ORAL SUSPENSION AND METHOD
US20040101521A1 (en) 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
US8058442B2 (en) 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
DE10336497B4 (de) * 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
JP2007536228A (ja) 2004-05-06 2007-12-13 サイデックス・インコーポレイテッド セルトラリンおよびスルホアルキルエーテルシクロデキストリンを含有するテイストマスク製剤
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1755579A4 (en) 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
JP2006150061A (ja) 2004-11-04 2006-06-15 Nec Corp ドラッグデリバリシステム及びそれに用いる薬剤カプセル並びに送信機
US20070197469A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
KR20080104329A (ko) 2006-02-22 2008-12-02 아놀드 뮤니히 데페리프론의 이용 및 철의 세포 내 미스핸들링으로부터 비롯된 프리드리히 운동실조증의 치료 및/또는 예방 방법
TWI404533B (zh) 2007-03-28 2013-08-11 Apotex Technologies Inc 去鐵酮（ｄｅｆｅｒｉｐｒｏｎｅ）之氟化衍生物
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds

Also Published As

Publication number Publication date
NZ579928A (en) 2012-09-28
ZA200906712B (en) 2011-02-23
US20080242706A1 (en) 2008-10-02
WO2008116301A1 (en) 2008-10-02
EP2134688B1 (en) 2016-10-05
CA2681545C (en) 2013-10-01
EP2134688A1 (en) 2009-12-23
AU2008232262A1 (en) 2008-10-02
TWI404533B (zh) 2013-08-11
CA2681545A1 (en) 2008-10-02
IL201189A (en) 2015-06-30
AU2008232262B2 (en) 2013-02-14
CN102964296A (zh) 2013-03-13
IL201189A0 (en) 2010-05-17
MX2009010407A (es) 2009-12-01
TW200843760A (en) 2008-11-16
UY30986A1 (es) 2008-09-02
NZ600874A (en) 2013-01-25
CN102964296B (zh) 2015-03-25
CN101679263A (zh) 2010-03-24
CL2008000887A1 (es) 2008-05-30
US8673943B2 (en) 2014-03-18
US8026261B2 (en) 2011-09-27
AR065880A1 (es) 2009-07-08
EP2134688A4 (en) 2011-01-19
US20120095061A1 (en) 2012-04-19
CN101679263B (zh) 2014-01-15
CA2627529A1 (en) 2008-09-28

Similar Documents

Publication Publication Date Title
PE20081596A1 (es) Derivados fluorinados de deferiprona
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
MA32903B1 (fr) Inhibiteurs de proteine-kinases
CY1110014T1 (el) Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm)
PE20140918A1 (es) Compuestos de benzoxepina inhibidores de la pi3k
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
TW200639159A (en) Treatment of pain
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
IN2012DN02502A (es)
PE20142421A1 (es) Fenilimidazopirazoles sustituidos y su uso
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
CR10410A (es) Carboxamidas sustituidas.
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed